Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ECEiline CaiHTH E TurnerIMIbrahim N. Muhsen

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows comparable overall response and mortality in relapsed AML, suggesting shorter venetoclax regimens may be effective.

Key Points

  • Overall response rate was 70% with a 14-day venetoclax regimen in adults with Acute Myeloid Leukemia.
  • Complete response rates aligned closely with the VIALE-A trial despite a diverse patient population.
  • Retrospective analysis assessed safety and outcomes of venetoclax combined with azacitidine or decitabine.
  • Findings highlight the need for prospective trials to establish optimal venetoclax treatment duration.

Cite This Study

Cai et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d378https://doi.org/10.1182/blood-2025-6994
View Full Paper
Ask AI
Bookmark
Share